Medications for Borderline Personality Disorder: A Ranking

Topiramate and aripiprazole lead the pack, but no drug treats the whole disorder

STUDY: Gerolymos C et al, Molecular Psychiatry 2026

STUDY TYPE: Systematic review and network meta-analysis

FUNDING: Independent

Background

Medications do not have great evidence in borderline personality disorder, and some argue that they can be countertherapeutic to the treatment goals. Those limitations aside, this network meta-analysis pooled 35 randomized controlled trials to compare 26 medications head-to-head across 12 symptom domains.

The Study

• 2,551 adults with borderline personality disorder across 35 randomized controlled trials.
• 26 medications compared against placebo or each other across 12 symptom dimensions: hostility, anger, anger control, aggressiveness, impulsivity, emotional dysregulation, anxiety, somatization, psychotic and paranoid symptoms, social functioning, and global severity.
• Trials lasted 6 to 16 weeks.

Topiramate (200–250 mg/day) produced the largest and most reliable reductions in hostility, anger, aggressiveness, and anger control, with high-quality evidence.

Aripiprazole (15 mg/day) reduced hostility, anger, psychotic and paranoid symptoms, and global severity, with moderate-quality evidence.

Lamotrigine (50–200 mg/day) matched topiramate on hostility and anger, though the lamotrigine samples were small.

Carbamazepine was the only drug that reduced impulsivity, though with low-quality evidence.

Asenapine was the only drug to improve emotional dysregulation, with very low-quality evidence.

No drug reduced suicidal behavior. Haloperidol worsened social functioning. Alprazolam produced a high rate of behavioral worsening. Valproate helped with anger control in one good-quality trial, but its teratogenic risk argues against its use in women of childbearing age.

Among the antidepressants, SSRIs have the best evidence in borderline personality disorder, but they didn’t rise up as particularly effective in this analysis. This may have more to do with the trial designs than the medications. Borderline personality disorder is also a risk factor for mood-worsening on antidepressants, and tricyclics in particularly can cause irritability and impulsivity in this population (and lethal overdose).

Early trials of amphetamines were abandoned in borderline because they caused paranoia, agitation, and violence. Methylphenidate and clonidine have a safer record if there is comorbid ADHD.

Omega-3 also failed to stand apart here, though in other analyses it held its ground with a consistent, moderate effect size across multiple symptoms in several small controlled trials.

Practice Implications

1. Network meta-analysis is a flawed technique, and the data it pulls on here is limited, so take these observations as hypothesis generating. Your patients responses might differ significantly.
2. I’d start with omega-3’s, use medications for comorbidities, and focus on non-symptomatic goal setting in line with Good Psychiatric Management of borderline personality disorder.